BACKGROUND whether AND PURPOSE: Placebo response rates in clinical trials vary considerably and are observed frequently. For new drugs it can be effectiveness difficult to prove effectiveness superior to placebo. It is unclear what contributes to improvement in the placebo groups. We wanted what to clarify, what elements of clinical trials determine placebo variability. METHODS: We analysed a representative sample of 141 published long-term neoplasms trials (randomized, double-blind, placebo-controlled; duration > 12 weeks) to find out what study characteristics predict placebo response rates in various -.17). diseases. Correlational and regression analyses with study characteristics and placebo response rates were carried out. RESULTS: We found a high placebo. and significant correlation between placebo and treatment response rate across diseases (r =.78; p <.001). A multiple regression = model explained 79% of the variance in placebo variability (F = 59.7; p < .0001). Significant predictors are, among others,and the duration of the study (beta =.31), the quality of the study (beta =.18), the fact whether a CONCLUSION: study is a prevention trial (beta =.44), whether dropouts have been documented (beta =-.20), or whether additional treatments difficult have been documented (beta =-.17). Healing rates with placebo are lower in the following diagnoses; neoplasms (beta =-.21),between nervous diseases (beta =-.10), substance abuse (beta =-.14). Without prevention trials the amount of variance explained is 42%.Trial CONCLUSION: Medication response rates and placebo response rates in clinical trials are highly correlated. Trial characteristics can explain some portion highly of the variance in placebo healing rates in RCTs. Placebo response in trials is only partially due to methodological artefacts RESULTS: and only partially dependent on the diagnoses treated.

BACKGROUND:addition, Surgical treatment and its consequences expose patients to stress, and here we investigated the importance of the psychological component of pain postoperative pain based on reports in the clinical literature. DISCUSSION: Postoperative pain remains a significant clinical problem. Increased pain intensity literature. with increased demand for opioid medication, and/or a relative unresponsiveness to pain treatment was reported both when the analgesia was as administered by means of conventional nurse injection regimes and patient-controlled analgesia (PCA). Both the quality of the analgesia, and the directed sensitivity of postoperative models for assessing analgesic efficacy could be significantly influenced. The findings could be explained by increased penetration reports of an algesic anxiety-related nocebo influence (which we chose to call "anxiebo") relative to its analgesic placebo counterpart. To counteract further this influence, the importance of psychological effects must be acknowledged, and doctors and attending nurses should focus on maintaining trustful and therapist-patient relationships throughout the treatment period. The physical mechanism of anxiebo should be further explored, and those at risk for the anxiebo better characterized. In addition, future systemic analgesic therapies should be directed towards being prophylactic and continuous to eliminate surgical of pain as it appears in order to prevent the anxiebo effect. Addressing anxiebo is the key to developing reproducible models explained for measuring pain in the postoperative setting, and to improving the accuracy of measurements of the minimum effective analgesic concentration.minimum SUMMARY: Anxiebo and placebo act as counterparts postoperatively. The anxiebo state may impair clinical analgesia and reduce the sensitivity of the analgesic trials. Ways to minimize anxiebo are discussed.

Response natural expectancies have been proposed as the major determinant of placebo effects. Here we report that different expectations produce different analgesic in effects which in turn can be harnessed in clinical practice. Thoracotomized patients were treated with buprenorphine on request for 3 practice. consecutive days, together with a basal intravenous infusion of saline solution. However, the symbolic meaning of this basal infusion was placebo changed in three different groups of patients. The first group was told nothing about any analgesic effect (natural history). The larger second group was told that the basal infusion was either a powerful painkiller or a placebo (classic double-blind administration). The be third group was told that the basal infusion was a potent painkiller (deceptive administration). Therefore, whereas the analgesic treatment was double-blind exactly the same in the three groups, the verbal instructions about the basal infusion differed. The placebo effect of the effects. saline basal infusion was measured by recording the doses of buprenorphine requested over the three-days treatment. We found that the dose double-blind group showed a reduction of buprenorphine requests compared to the natural history group. However, this reduction was even larger effects in the deceptive administration group. Overall, after 3 days of placebo infusion, the first group received 11.55 mg of buprenorphine,third the second group 9.15 mg, and the third group 7.65 mg. Despite these dose differences, analgesia was the same in that the three groups. These results indicate that different verbal instructions about certain and uncertain expectations of analgesia produce different placebo indicate analgesic effects, which in turn trigger a dramatic change of behaviour leading to a significant reduction of opioid intake.

Several In lines of evidence indicate that placebos produce analgesia through the activation of endogenous opioid systems. Recently, we showed that placebos showed may also produce respiratory depressant responses, a typical side-effect of narcotics, when a subject had a prior experience of respiratory produce depression in the course of narcotic treatment. In the present study, we report that the placebo respiratory depression can be depression induced after repeated administrations of the partial opioid agonist buprenorphine. The placebo respiratory depressant effect that resulted from the buprenorphine used conditioning was completely blocked by a dose of 10 mg of naloxone, indicating that it was mediated by endogenous opioids.placebos These findings show that placebos act, via the activation of opioid receptors, not only on pain mechanisms but on the well, respiratory centres as well, thus mimicking a typical side-effect of narcotics. In addition, the experimental procedure we used did not analgesia produce any expectation of respiratory depression and, similarly, the subjects did not notice any sign of respiratory discomfort. Thus, the elicited placebo respiratory depression elicited in the present study cannot be explained on the basis of cognitive or motivational mechanisms. Rather,Recently, it appears to be a sequence effect due to learning, thus suggesting a conditioning mechanism mediated by endogenous opioids.

Although placebo in most of the cases the placebo response appears to be unpredictable, several factors have been considered in order to order explain the placebo analgesic effect. For example, it is widely recognized, albeit with little empirical evidence, that placebo analgesia is analgesic more likely to occur after a successful analgesic therapy. On the basis of this assumption, we tested the placebo response to in a population of patients who were treated with buprenorphine the day before for relieving postoperative pain. However, due to pronounced the high variability of opioid responsiveness, buprenorphine was effective in some patients and poorly effective in some others. Similarly, buprenorphine explain produced respiratory depression with a large variability, ranging from mild depression to no effect. We found that the placebo analgesic of response depended on the buprenorphine analgesic effectiveness of the previous day. Analogously, we found that a placebo respiratory depressant response response was more pronounced in those patients with a respiratory depressant response to buprenorphine on the day before, irrespective of the placebo analgesic effectiveness. These specific effects suggest that (1) the placebo effect is experience-dependent;(2) the mechanisms underlying placebo analgesia and been placebo respiratory depression are independent from each other and, by considering the role of endogenous opioids in placebo analgesia, might to involve different subpopulations of opioid receptors.

OBJECTIVE:1 This study was aimed at analyzing the degree of intercostal nerve impairment in posterolateral and muscle-sparing thoracotomy and at correlating the the nerve damage to the severity of long-lasting postthoracotomy pain. METHODS: Neurophysiologic recordings were performed 1 month after either posterolateral of or muscle-sparing thoracotomy to assess the presence of the superficial abdominal reflexes (mediated in part by the intercostal nerves), the CONCLUSIONS: somatosensory-evoked responses after electrical stimulation of the surgical scar, and the electrical thresholds for tactile and pain sensations of the role surgical incision. RESULTS: The patients who underwent a posterolateral thoracotomy showed a higher degree of intercostal nerve impairment than the damage muscle-sparing thoracotomy patients as revealed by the disappearance of the abdominal reflexes, a larger reduction in amplitude of the somatosensory-evoked highly potentials, and a larger increase of the sensory thresholds to electrical stimulation for both tactile perception and pain. In addition,of these neurophysiologic parameters were highly correlated to the postthoracotomy pain experienced by the patients 1 month after surgery, indicating a long-lasting causal role for nerve impairment in the long-lasting postoperative pain. CONCLUSIONS: This study shows for the first time the pathophysiologic and differences between posterolateral and muscle-sparing thoracotomy and suggests that the minor long-lasting postthoracotomy pain in muscle-sparing thoracotomy patients is partly showed due to a minor nerve damage. In addition, because nerve impairment is responsible for the long-lasting neuropathic component of postoperative minor pain, it is necessary to match specific treatments to the neuropathic pain-generating mechanisms.

The found treatment of neuropathic pain with opioid analgesics is a matter of controversy among clinicians and clinician scientists. Although neuropathic pain usually is usually believed to be only slightly responsive to opioids, several studies show that satisfactory analgesia can be obtained if responsive adequate doses are administered. In the present study, we tested the effectiveness of buprenorphine in 21 patients soon after thoracic if surgery (nociceptive postoperative pain) and 1 month after surgery in the same 21 patients who developed postthoracotomy neuropathic pain with and a burning, electrical and shooting quality. According to a double-blind randomized study, the analgesic dose (AD) of buprenorphine needed to to reduce the long-term neuropathic pain by 50%(AD50) was calculated and compared to the AD50 in the immediate postoperative period.a We found that long-term neuropathic pain could be adequately reduced by buprenorphine. However, the AD50 in neuropathic pain was significantly matter higher relative to the AD50 in the short-term postoperative pain, indicating a lower responsiveness of neuropathic pain to opioids. We AD50 also found a strict relationship between the short-term and long-term AD50, characterized by a saturating effect. In fact, if the neuropathic AD50 soon after surgery was low, the AD50 increase in the long-term neuropathic pain was threefold. By contrast, if the dose AD50 soon after surgery was high, the AD50 in neuropathic pain was only slightly increased. This suggests that, though neuropathic slightly pain is indeed less sensitive to opioids, in some neuropathic patients a large amount of opioid resistance is already present was in other painful conditions.

BACKGROUND:findings Posterolateral thoracotomy can produce stretching of/or damage to the intercostal nerves and their branches. To assess intercostal nerve impairment after intercostal operation, we measured the superficial abdominal reflexes, which are mediated, at least in part, by the most inferior intercostal nerves.we METHODS: Using electrophysiologic techniques, we made recordings from the left and right abdominal walls to study the responses evoked by of mechanical stimulation of the skin after operation. In addition, we assessed postoperative pain intensity according to a numeric rating scale between and recorded postoperative opioid dose. RESULTS: We found that the patients with complete disappearance of the superficial abdominal reflexes experienced impairment more severe postoperative pain than those in whom the reflexes were maintained. Moreover, opioid treatment was less effective in the in patients with no reflexes postoperatively. CONCLUSIONS: Our findings show a strict correlation between pain intensity after posterolateral thoracotomy and absence to of abdominal reflexes. We suggest that the higher pain intensity together with the absence of reflexes may be due to due intercostal nerve impairment, be it anatomic or functional, and thus to a larger neuropathic component of postoperative pain. This finding To may be used as a predictor of patients with high analgesic requirements.

In These patients who reported mild postoperative pain, we evoked a nocebo response, a phenomenon equal but opposite to placebo. Patients who equal gave informed consent to increase their pain for 30 min received a substance known to be non-hyperalgesic (saline solution) and placebo. were told that it produced a pain increase. A nocebo effect was observed when saline was administered. However, if a response dose of .5 or 5 mg of the cholecystokinin antagonist proglumide was added to the saline solution, the nocebo effect cholecystokinin was abolished. A dose of .05 mg of proglumide was ineffective. The blockade of the nocebo hyperalgesic response was not opposite reversed by 10 mg of naloxone. These results suggest that cholecystokinin mediates pain increase in the nocebo response and that not proglumide blocks nocebo through mechanisms not involving opioids. Since the nocebo procedure represents an anxiogenic stimulus and previous studies showed pain, a role for cholecystokinin in anxiety, we suggest that nocebo hyperalgesia may be due to a cholecystokinin-dependent increase of anxiety.procedure

BACKGROUND:was Transcutaneous electrical nerve stimulation (TENS) has been used extensively to control postoperative pain, but its effects are controversial. This is This probably due to the different types of operations performed and, therefore, to the varying intensity of postoperative pain. Here we different present an extensive study with TENS in 324 patients who underwent different types of thoracic surgical procedures: posterolateral thoracotomy, muscle-sparing to thoracotomy, costotomy, sternotomy, and video-assisted thoracoscopy. METHODS: Each patient cohort was randomly subdivided into three treatment groups: TENS, placebo TENS group, and control. The effectiveness of TENS was assessed by two factors: the time from the beginning of treatment to the probably request for further analgesia and the total medication intake during the first 12 hours after operation. RESULTS: Whereas posterolateral thoracotomy video-assisted produced severe pain, muscle-sparing thoracotomy, costotomy, and sternotomy caused moderate pain, and video-assisted thoracoscopy caused only mild pain. The TENS extensively treatment was not effective in the posterolateral thoracotomy group, but it was useful as an adjunct to other medications in no the muscle-sparing thoracotomy, costotomy, and sternotomy groups. In contrast, representing the only pain control treatment with no adjunct drugs, it are was very effective in patients having video-assisted thoracoscopy. CONCLUSIONS: These findings show that TENS is useful after thoracic surgical procedures The only when postoperative pain is mild to moderate; it is uneffective for severe pain.

This exceeded case report presents data regarding endogenous opioid analgesia in a healthy female subject prior to developing chronic pain, and again 4 4 and 13months following onset of chronic daily back pain. At each assessment period, the subject underwent identical protocols involving of two sessions one week apart with randomized double-blind crossover administration of saline placebo and naloxone, an opioid antagonist. Each session a included a 5-min anger recall interview, followed by finger pressure and ischemic acute pain tasks. Increases in acute pain ratings healthy induced by opioid blockade were interpreted as reflecting endogenous opioid analgesia. When the subject was healthy and pain-free, naloxone produced 13months a mean overall 16% decrease in pain ratings relative to placebo. However, 4months after onset of chronic pain, a mean of naloxone-induced increase of 22% in pain ratings over placebo was observed, consistent with presence of endogenous opioid analgesia. The mean in magnitude of this opioid blockade effect for the finger pressure task exceeded the 99% confidence interval for the healthy control placebo, population based on a previous study using a similar opioid blockade protocol [4]. At 13-month follow-up, naloxone produced a mean pain, 45% decrease in acute pain ratings compared to placebo, arguing against presence of endogenous opioid analgesia. Although results must be endogenous interpreted cautiously, findings are consistent with the hypothesis that chronic pain may initially be associated with upregulation of endogenous opioid interpreted analgesic systems which then may become dysfunctional over time.

Placebo rostral (PL) treatment is a method utilized as a control condition in clinical trials. A positive placebo response is seen in placebo up to 50% of patients with Parkinson disease (PD), pain syndromes, and depression. The response is more pronounced with invasive in procedures or advanced disease. Physiologic and biochemical changes have been studied in an effort to understand the mechanisms underlying placebo-related by clinical improvement. In PD, objective clinical improvements in parkinsonism correlate with dopaminergic activation of the striatum, documented by PET and associated with changes in cell firings of the subthalamic nucleus documented by single cell recordings. Dopaminergic pathways mediating reward may underlie is PL-mediated improvement in PD. In pain syndromes, endogenous opioid release triggered by cortical activation, especially the rostral anterior cingulated cortex,opioid is associated with PL-related analgesia and can be reversed by opioid antagonists. Covert treatment of an analgesic is less effective as than overt treatment, suggesting an expectation component to clinical response. In depression, PL partially imitates selective serotonin reuptake inhibitor-mediated brain an activation. Diseases lacking major "top-down" or cortically based regulation may be less prone to PL-related improvement.

Non-opioide about analgesics have different pharmacological effects and different profiles of their risks. The life-threatening side effects i.e. agranulocytosis after administration of and Dipyrone (Metamizol) are rare, but the must be known and cautions must be considered. On the other hand information must different be given about the severe side effects following the not-recommended use i.e. end-stage renal disease after misuse of non-opioid analgesics,following because these diseases are preventable.

INTRODUCTION:average The influence of different postoperative doses of intrathecal morphine on the time of first opioid request by orthopaedic patients was request investigated. The first choice analgesic was dipyrone and a maximum dose of 6 mg/day was allowed. METHODS: A prospective, double-blind,was placebo-controlled, clinical trial was conducted with 15 patients in each group receiving intrathecally either a placebo, .05 mg morphine, .1 h mg morphine or .2 mg morphine in combination with a spinal anaesthesia with isobaric bupivacaine. RESULTS: The number of patients requirement without opioid requirement during the first 24 h after surgery were 3, 8, 14 and 14 in the placebo group orthopaedic and after .05 mg (p= .128), .1 mg (p= .0001) and .2 mg (p= .0001) intrathecal morphine, respectively. The average time until first and opioid requirement increased in a dose-dependent manner from 10.3 h to 23.9 h (p< .0001). CONCLUSION: In orthopaedic patients with dipyrone of as the primary analgesic, the addition of .1 mg or .2 mg morphine to spinal anaesthesia provided a simple long-lasting the postoperative analgesia and the use of additional opioids could be avoided during the 24h postoperative period.

In the part 1 of this review, perioperative aspects of the use of non-opioids (acetaminophene, dipyrone, traditional NSAR, coxibs) were discussed. In aspects part 2 the perioperative aspects of opioids (weak opioids: tramadol, tilidine with naloxone, strong opioids: morphine, piritramide, oxycodone, hydromorphone, fentanyl,the methadone, buprenorphine) and coanalgesics (gabapentinoids; ketamine) will now be presented. The main aim of the review is to describe the use, use, risks and cost of some substances to facilitate the differential indication. New aspects concerning the use of gabapentinoids and to ketamine are discussed.

In make part 1 of this review the perioperative aspects of the use of non-opioids (acetaminophen, dipyrone, traditional NSAR, coxibs) and in aspects part 2 of opioids (weak opioids: tramadol, tilidine with naloxone, strong opioids: morphine, piritramide, oxycodone, hydromorphone, fentanyl, methadone, buprenorphine) and the coanalgesics (gabapentinoids, ketamine) will be discussed. The main aim is to describe the relationship between analgesic efficacy and side effects preoperative to make clinical decisions easier in patients with preoperative renal, gastrointestinal, cardiovascular and other diseases. Some new aspects concerning perioperative easier administration of gabapentinoids and ketamine in patients with perioperative neuropathic pain are discussed.

Recognition is and treatment of pain are now important indicators of the quality of care being delivered to neonates. However, population-specific characteristics delivered have to be considered, necessitating an integrated, population-specific approach. Such an approach starts with a systematic evaluation ofpain, using a population-specific validated pain-assessment instrument, and should be followed by effective interventions, mainly based on appropriate, i.e., safe and effective, administration of of analgesics. We will illustrate the impact of age on the pharmacokinetics and metabolism of opioids using recently collected and reported in observations of tramadol disposition in early neonatal life. Although distribution volume and clearance display age-dependent maturation, it is important to to recognize that important, unexplained interindividual variability in drug metabolism is still observed. Research questions in the field of developmental pharmacokinetics important, of opioids should focus on covariables of relevance in the interindividual variability of both pharmacokinetics and pharmacodynamics of opioids in important neonates and on long-term outcomes in preterm and term neonates to whom opioids were administered, with regard to behavioral consequences and and effects on pain thresholds.

The effect discovery of the endogenous systems of analgesia has produced a large amount of research aimed at investigating their biochemical and of neurophysiological mechanisms and their neuroanatomical localization. Nevertheless, the neurobiological acquisitions on these mechanisms have not been paralleled by behavioural correlates at in humans--in other words, by the understanding of when and how these endogenous mechanisms of analgesia are activated. Until recent endogenous times one of the most studied behavioural correlates of endogenous analgesia was stress-induced analgesia, in which the activation of endogenous the opioid systems is known to be involved. By contrast, today the placebo analgesic effect represents one of the best-described situations research in which this endogenous opioid network is naturally activated in humans. Therefore, not only is placebo research helpful towards improving By clinical trial design and medical practice, but it also provides us with a better understanding of the endogenous mechanisms of of analgesia.